Loading…
Vegewax Candleworx Ltd., a drug manufacturing facility in Canada, failed to comply with Current Good Manufacturing Practice (CGMP) regulations for over-the-counter drug products during an FDA inspection conducted in October 2023. The company did not perform adequate identity and purity testing on component lots, including active pharmaceutical ingredients, instead relying solely on supplier certificates of analysis without establishing their reliability. Additionally, the firm failed to test for specified contaminants in certain components used in their drug manufacturing process. These violations rendered the company's drug products adulterated under federal law.